Q-omics provides the consensus-scored MTHFSD profile across patient tissues and cancer cell-line models. MTHFSD expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MTHFSD is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, MTHFSD RNA expression shows 19,418 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where MTHFSD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTHFSD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTHFSD survival associations across molecular data types. MTHFSD RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTHFSD RNA expression–survival associations across cancer types. High MTHFSD expression shows unfavorable associations in ACC, COAD, LGG, LUSC and KIRC, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify ACC as the clearest survival context for MTHFSD RNA expression.
This table summarizes MTHFSD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MTHFSD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTHFSD shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, LIHC, BLCA and STAD. The HNSC box plot shows higher MTHFSD RNA expression in tumor versus normal tissue (log2 FC = +0.736, t-test p < 0.001).
This table shows molecular features associated with MTHFSD in patient tissues and cancer cell lines. In patient samples, MTHFSD shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTHFSD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_NSCLC_LUAD.
